ArticleAdvanced functional materials2026
Germanane Quantum Dots Promote Metabolic Reprogramming of Immune Cells Toward Regulatory T Cells and Suppress Inflammation In Vitro and In Vivo.
Article in Advanced functional materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, nanomaterials have emerged as a tool in developing novel therapies against inflammatory diseases. Metabolic changes in immune cells direct the phenotype and function of the host immune system. Therefore, next-generation immunomodulatory biomaterials should be designed to target metabolic pathways and trigger specific changes in immune cells to direct their fate toward an anti-inflammatory phenotype. The current study reports the fabrication and first application of germanane quantum dots (GeHQDs) to modulate inflammation in cell culture and in vivo mouse model. Using rational design and synthesis strategies, our GeHQDs leverage the intrinsic anti-inflammatory properties of germanane to provide a novel nanoplatform to trigger metabolic reprogramming of immune cells toward an anti-inflammatory phenotype. These GeHQDs are spontaneously uptaken into the immune cells and trigger a switch in their phenotype toward regulatory T (Treg) cells. Metabolomic analysis suggested a downregulation in glycolytic flux and upregulation in fatty acid oxidation with an increase in mitochondrial respiration in the GeHQDs-treated group, which is a typical signature of Treg cells. In an in vivo mouse model of systemic inflammation, GeHQDs treatment upregulated the circulating Treg cell number, improved the metabolomic profile and downregulated inflammation. The current study presents a new paradigm in targeting inflammatory diseases by modulating immune cell metabolism using next-generation nanomaterials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.